HK1066462A1 - Visual function improving agents - Google Patents

Visual function improving agents

Info

Publication number
HK1066462A1
HK1066462A1 HK04109315.5A HK04109315A HK1066462A1 HK 1066462 A1 HK1066462 A1 HK 1066462A1 HK 04109315 A HK04109315 A HK 04109315A HK 1066462 A1 HK1066462 A1 HK 1066462A1
Authority
HK
Hong Kong
Prior art keywords
visual function
improving agents
function improving
agents
visual
Prior art date
Application number
HK04109315.5A
Other languages
English (en)
Inventor
Yoshiko Takayama
Yukuo Yoshida
Masayoshi Uehata
Original Assignee
Senju Pharma Co
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co, Mitsubishi Tanabe Pharma Corp filed Critical Senju Pharma Co
Publication of HK1066462A1 publication Critical patent/HK1066462A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK04109315.5A 2001-04-11 2004-11-25 Visual function improving agents HK1066462A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001113329 2001-04-11
JP2001308010 2001-10-03
PCT/JP2002/003590 WO2002083175A1 (fr) 2001-04-11 2002-04-11 Agents ameliorant la fonction visuelle

Publications (1)

Publication Number Publication Date
HK1066462A1 true HK1066462A1 (en) 2005-03-24

Family

ID=26613462

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04109315.5A HK1066462A1 (en) 2001-04-11 2004-11-25 Visual function improving agents

Country Status (8)

Country Link
US (2) US7109208B2 (xx)
EP (1) EP1378247B1 (xx)
JP (2) JP4204326B2 (xx)
KR (2) KR100883077B1 (xx)
CN (2) CN101310771B (xx)
CA (2) CA2707827A1 (xx)
HK (1) HK1066462A1 (xx)
WO (1) WO2002083175A1 (xx)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153605A1 (de) * 2001-11-02 2003-05-28 Morphochem Ag Komb Chemie Verwendung von Inhibitoren der Rho-Kinasen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens
WO2004039366A1 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
EP1616577B1 (en) * 2003-04-18 2011-09-21 Senju Pharmaceutical Co., Ltd. 2-chloro-6,7-dimethoxy-N-5 [5-(1)H- indazolyl]quinazoline-4-amine, N-(1-benzyl-4-piperidinyl)-1H-indazole-5-amine dihydrochloride, 4-[2-(2,3,4,5,6-pentafluorophenyl)acryloyl]cinnamic acid and fasudil hydrochloride for use in repairing corneal perception.
CA2541069C (en) * 2003-10-03 2012-08-14 Michael S. H. Chu Systems and methods for delivering a medical implant to an anatomical location in a patient
CA2550361C (en) 2003-12-19 2014-04-29 Prabha Ibrahim Compounds and methods for development of ret modulators
ES2553953T3 (es) 2004-06-03 2015-12-15 Senju Pharmaceutical Co., Ltd. Fármaco para la recuperación de la percepción corneal que contiene un compuesto amida
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20090234005A1 (en) * 2005-03-31 2009-09-17 Naruhiro Ishida Protective agent for retinal neuronal cell containing prostaglandin f2alpha derivative as active ingredient
CN101160128B (zh) * 2005-04-13 2010-08-18 宇部兴产株式会社 含有吲唑衍生物作为有效成分的视网膜神经细胞保护剂
KR20080027775A (ko) 2005-05-17 2008-03-28 플렉시콘, 인코퍼레이티드 피롤(２,３-ｂ)피리딘 유도체 단백질 키나제 억제제
WO2007002325A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
KR20090057223A (ko) * 2006-07-31 2009-06-04 센주 세이야꾸 가부시키가이샤 아미드 화합물을 함유하는 수성 액제
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
JP5313125B2 (ja) 2007-02-28 2013-10-09 旭化成ファーマ株式会社 スルホンアミド誘導体
US8895507B2 (en) * 2007-04-16 2014-11-25 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptogenesis
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
US9248125B2 (en) 2007-08-29 2016-02-02 Senju Pharmaceutical Co., Ltd. Agent for promoting corneal endothelial cell adhesion
GB0723825D0 (en) * 2007-12-05 2008-01-23 Ucl Business Plc Composition
EP2319539A4 (en) * 2008-07-24 2012-03-28 Univ Osaka PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2010024903A1 (en) * 2008-08-29 2010-03-04 Yangbo Feng BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS
MX2011008303A (es) 2009-04-03 2011-11-29 Plexxikon Inc Composiciones del acido propano-1-sulfonico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil}-amida y el uso de las mismas.
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
PE20121327A1 (es) 2009-11-06 2012-10-18 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello
WO2011080984A1 (en) * 2009-12-29 2011-07-07 Senju Pharmaceutical Co., Ltd. Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
JP2012006918A (ja) * 2010-05-27 2012-01-12 Santen Pharmaceut Co Ltd イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤
TW201202214A (en) * 2010-05-27 2012-01-16 Santen Pharmaceutical Co Ltd Novel indazole derivative or salt thereof, production intermediate thereof, and prophylactic or therapeutic agent for chorioretinal degeneratire disease using the same
RU2452436C1 (ru) * 2011-01-31 2012-06-10 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения атрофии зрительного нерва сосудистого генеза
RS58455B1 (sr) 2011-02-07 2019-04-30 Plexxikon Inc Jedinjenja i postupci za modulaciju kinaze, i indikacije za njih
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
CA2859832C (en) * 2011-12-20 2015-07-14 Research Foundation Of The City University Of New York Method for screening a drug in retinal tissue
JP6218229B2 (ja) 2011-12-28 2017-10-25 京都府公立大学法人 角膜内皮細胞の培養正常化
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP2990040B1 (en) 2013-04-24 2019-12-04 Kyushu University, National University Corporation Therapeutic agent for eyeground disease
JP6548576B2 (ja) 2013-07-30 2019-07-24 京都府公立大学法人 角膜内皮細胞マーカー
JPWO2015029923A1 (ja) * 2013-08-26 2017-03-02 ロート製薬株式会社 眼科用製剤
JPWO2015064768A1 (ja) 2013-10-31 2017-03-09 京都府公立大学法人 角膜内皮の小胞体細胞死関連疾患治療薬
JP6470286B2 (ja) 2013-11-27 2019-02-13 京都府公立大学法人 ラミニンの角膜内皮細胞培養への応用
JP2015229671A (ja) * 2014-06-06 2015-12-21 株式会社デ・ウエスタン・セラピテクス研究所 網膜色素上皮細胞保護剤
CN107073067A (zh) 2014-10-31 2017-08-18 京都府公立大学法人 使用层粘连蛋白的新的角膜的治疗
JP6770435B2 (ja) 2014-10-31 2020-10-14 京都府公立大学法人 ラミニンによる網膜および神経の新規治療
WO2017064119A1 (en) * 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
EP4088719A1 (en) * 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
ES2947826T3 (es) 2016-02-15 2023-08-21 Kyoto Prefectural Public Univ Corp Célula endotelial corneal funcional humana y aplicación de la misma
WO2018041824A1 (en) * 2016-08-29 2018-03-08 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical composition of ethacrynic acid
CA3102645A1 (en) * 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
JP7481329B2 (ja) * 2018-06-07 2024-05-10 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
CA3102598A1 (en) * 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
JPWO2020045642A1 (ja) 2018-08-31 2021-08-12 学校法人同志社 眼細胞を保存または培養するための組成物および方法
WO2020071438A1 (ja) 2018-10-02 2020-04-09 学校法人同志社 角膜内皮細胞を保存するための方法および容器
US20220242859A1 (en) * 2019-06-06 2022-08-04 Disarm Therapeutics, Inc. Inhibitors of sarm1
KR20220146552A (ko) 2020-02-27 2022-11-01 교토후고리츠다이가쿠호진 인간 기능성 각막 내피 세포 및 그 응용
AU2020454040A1 (en) * 2020-06-19 2023-02-09 Endogena Therapeutics, Inc. New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium
JPWO2023085369A1 (xx) 2021-11-11 2023-05-19

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
JPH0680054B2 (ja) 1985-06-19 1994-10-12 吉富製薬株式会社 ピペリジン誘導体
JP2770497B2 (ja) 1988-11-24 1998-07-02 吉富製薬株式会社 トランス―４―アミノ（アルキル）―１―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途
JP2720348B2 (ja) 1989-03-30 1998-03-04 旭化成工業株式会社 脳細胞機能障害改善剤
JP3408546B2 (ja) 1991-02-19 2003-05-19 旭化成株式会社 抗喘息剤
JP2864489B2 (ja) 1991-02-27 1999-03-03 吉富製薬株式会社 喘息治療剤
DE69231297T2 (de) 1991-09-06 2000-11-23 Yoshitomi Pharmaceutical Industries, Ltd. 4-amino(alkyl)cyclohexan-1-carboxamidverbindungen und ihre verwendung
JP3265695B2 (ja) 1992-05-12 2002-03-11 三菱ウェルファーマ株式会社 ４−置換アミノ（アルキル）シクロヘキサン−１−カルボン酸アミド化合物
JP2893029B2 (ja) 1992-08-10 1999-05-17 旭化成工業株式会社 心臓保護剤
JPH0680569A (ja) 1992-09-03 1994-03-22 Asahi Chem Ind Co Ltd 血小板凝集阻害剤
TW325997B (en) * 1993-02-02 1998-02-01 Senju Pharma Co Pharmaceutical composition for preventing and treating retinal diseases
JP3218356B2 (ja) 1993-03-31 2001-10-15 ヤンマー農機株式会社 管理機
JP3464012B2 (ja) 1993-04-05 2003-11-05 旭化成株式会社 精神症候治療剤
JPH0741424A (ja) 1993-07-28 1995-02-10 Asahi Chem Ind Co Ltd 抗炎症剤
JPH07277979A (ja) 1994-04-12 1995-10-24 Asahi Chem Ind Co Ltd 過粘性症候群治療または予防剤
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
JPH08231400A (ja) * 1995-02-24 1996-09-10 Rohto Pharmaceut Co Ltd イフェンプロジルを必須成分とする眼圧降下剤
US5906819A (en) 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
JP3421217B2 (ja) 1995-11-20 2003-06-30 麒麟麦酒株式会社 Ｒｈｏ標的タンパク質Ｒｈｏキナーゼ
US5641750A (en) 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
CA2240271C (en) 1995-12-21 2005-12-13 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
EP0868186B1 (en) 1995-12-21 2005-03-02 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
WO1997028130A1 (fr) 1996-02-02 1997-08-07 Nippon Shinyaku Co., Ltd. Derives de l'isoquinoline et medicaments associes
JPH09227381A (ja) 1996-02-29 1997-09-02 Asahi Chem Ind Co Ltd 脳血栓における運動麻痺の改善剤
US5733904A (en) 1996-04-10 1998-03-31 Asahi Kasei Kogyo Kabushiki Kaisha Method for prevention and treatment of viral infectious diseases for viral suppression
JPH10201480A (ja) * 1996-07-24 1998-08-04 Kirin Brewery Co Ltd ヒト由来のＲｈｏ標的タンパク質Ｒｈｏキナーゼおよびその遺伝子
JPH1087491A (ja) 1996-07-26 1998-04-07 Asahi Chem Ind Co Ltd 転写調節因子阻害剤
NZ513800A (en) 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
US6162428A (en) * 1997-02-12 2000-12-19 Layton Bioscience, Inc. hNT-neuron human neuronal cells to replace ganglion cells
JP2002506461A (ja) 1997-06-26 2002-02-26 メルク エンド カンパニー インコーポレーテッド 網膜及び視神経の健康の最適化方法
CA2214841A1 (en) 1997-10-31 1999-04-30 Lisa Mckerracher Rho antagonists and their use to block inhibition of neurite outgrowth
ATE324362T1 (de) 1998-05-25 2006-05-15 Santen Pharmaceutical Co Ltd Neue vinylbenzolderivate
KR100616466B1 (ko) 1998-08-17 2006-08-29 센주 세이야꾸 가부시키가이샤 녹내장 예방/치료제
WO2000057914A1 (fr) 1999-03-25 2000-10-05 Santen Pharmaceutical Co., Ltd. Agents permettant d'abaisser la tension oculaire
EP1064944A1 (en) * 1999-06-25 2001-01-03 Schering Aktiengesellschaft Protein kinase N inhibitor comprising Fasudil
JP2001081048A (ja) 1999-09-10 2001-03-27 Wakamoto Pharmaceut Co Ltd 眼圧降下剤
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
ATE327993T1 (de) * 2000-03-16 2006-06-15 Mitsubishi Pharma Corp Amid-verbindung und deren verwendung
JP4273821B2 (ja) 2003-04-21 2009-06-03 ヤマハ株式会社 音声データ処理プログラム
JP4264030B2 (ja) 2003-06-04 2009-05-13 株式会社ケンウッド 音声データ選択装置、音声データ選択方法及びプログラム

Also Published As

Publication number Publication date
JP2008247923A (ja) 2008-10-16
JPWO2002083175A1 (ja) 2004-08-05
KR20080047633A (ko) 2008-05-29
EP1378247A4 (en) 2007-07-25
KR100883077B1 (ko) 2009-02-10
KR100865262B1 (ko) 2008-10-24
CA2707827A1 (en) 2002-10-24
KR20040007495A (ko) 2004-01-24
US20040106646A1 (en) 2004-06-03
EP1378247B1 (en) 2016-08-24
CN1501813A (zh) 2004-06-02
US7696194B2 (en) 2010-04-13
EP1378247A8 (en) 2004-12-22
JP4204326B2 (ja) 2009-01-07
CN101310771A (zh) 2008-11-26
CN101310771B (zh) 2012-08-08
WO2002083175A1 (fr) 2002-10-24
US20060148852A1 (en) 2006-07-06
CA2443918A1 (en) 2002-10-24
CN100411686C (zh) 2008-08-20
EP1378247A1 (en) 2004-01-07
JP4802211B2 (ja) 2011-10-26
US7109208B2 (en) 2006-09-19
CA2443918C (en) 2012-06-05

Similar Documents

Publication Publication Date Title
HK1066462A1 (en) Visual function improving agents
DE60231477D1 (en) Imidazolderivate
IL160539A0 (en) Anti-influenzal agents
GB2376085B (en) Visual aid
AU2002313943A8 (en) Electromobile
GB0119382D0 (en) Voltsnips
AU2001100134A4 (en) Enviro-trap
GB0117985D0 (en) Flexi-pot
AU2002248005A1 (en) Visual function improving agents
AU2288P (en) Prime322 xTriticosecale
AU2479P (en) Crackerjack xTriticosecale
CA91502S (en) Bedboard
GB2376870B (en) Fatstopper
HU0100486D0 (en) Bolyhos spirit
GB0120289D0 (en) V place
GB0123001D0 (en) Q-card
AU144891S (en) Cupboard-sideboard
GB0112488D0 (en) Reactor-vision-2
GB0113819D0 (en) Uxb
GB0115418D0 (en) Textport
GB0117988D0 (en) Karricart-kc2000
GB0121233D0 (en) Vdex
GB0121611D0 (en) Pharmaceutically-useful-compounds
GB0104650D0 (en) Ergopad
GB0127179D0 (en) Degravitator

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 27 TO JOURNAL OF : [54] VISUAL FUNCTION DISORDER IMPROVING AGENTS

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140411